Wolfgang Korte1. 1. Institut für Klinische Chemie und Hämatologie, Kantonsspital, St Gallen, Switzerland. wolfgang.korte@ikch.ch
Abstract
INTRODUCTION: The association of cancer and venous thromboembolism (VTE) becomes increasingly important. VTE has been recognised as an increasingly frequent complication in cancer care. Furthermore, recent clinical trials have shown that therapy and prophylaxis of VTEs with low-molecular weight heparin (LMWH) is, in general, superior to oral anticoagulation with warfarin. Also, prolonged therapy of or prophylaxis for VTE in cancer patients seems to be associated with an improved outcome. DISCUSSION: Research on patient preferences for therapy and prophylaxis of VTE is still rare; but it seems clear that, as in other areas, cancer patients wish to be involved in the decision-making process. Patients seem to accept LMWH over oral anticoagulation despite the need for subcutaneous injections. CONCLUSION: Cancer and thrombosis/hypercoagulability is an increasingly important association. The use of antithrombotics in cancer patients warrants increased attention since it's importance seems underrecognized.
INTRODUCTION: The association of cancer and venous thromboembolism (VTE) becomes increasingly important. VTE has been recognised as an increasingly frequent complication in cancer care. Furthermore, recent clinical trials have shown that therapy and prophylaxis of VTEs with low-molecular weight heparin (LMWH) is, in general, superior to oral anticoagulation with warfarin. Also, prolonged therapy of or prophylaxis for VTE in cancerpatients seems to be associated with an improved outcome. DISCUSSION: Research on patient preferences for therapy and prophylaxis of VTE is still rare; but it seems clear that, as in other areas, cancerpatients wish to be involved in the decision-making process. Patients seem to accept LMWH over oral anticoagulation despite the need for subcutaneous injections. CONCLUSION:Cancer and thrombosis/hypercoagulability is an increasingly important association. The use of antithrombotics in cancerpatients warrants increased attention since it's importance seems underrecognized.
Authors: Agnes Y Y Lee; Frederick R Rickles; Jim A Julian; Michael Gent; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Mark N Levine Journal: J Clin Oncol Date: 2005-02-07 Impact factor: 44.544
Authors: Ajay K Kakkar; Mark N Levine; Zbigniew Kadziola; Nicholas R Lemoine; Vanessa Low; Heman K Patel; Gordon Rustin; Michael Thomas; Mary Quigley; Robin C N Williamson Journal: J Clin Oncol Date: 2004-05-15 Impact factor: 44.544
Authors: Paolo Prandoni; Anthonie W A Lensing; Andrea Piccioli; Enrico Bernardi; Paolo Simioni; Bruno Girolami; Antonio Marchiori; Paola Sabbion; Martin H Prins; Franco Noventa; Antonio Girolami Journal: Blood Date: 2002-07-12 Impact factor: 22.113
Authors: Verena Gartner; Katharina A Kierner; Astrid Namjesky; Birgit Kum-Taucher; Bernhard Hammerl-Ferrari; Herbert H Watzke; Cornelia Stabel Journal: Support Care Cancer Date: 2011-11-26 Impact factor: 3.603